Fractyl’s Gene Therapy Breakthrough, Verdiva’s Oral GLP-1 Pipeline, Viking’s Phase 3 Launch & More
In this week’s Obesity Updates, we spotlight the most compelling developments shaping the obesity treatment landscape—from gene therapies and oral GLP-1 innovations to regulatory shifts and long-term adherence insights.
🔬 Key Highlights This Week:
🧬 Fractyl’s GLP-1 gene therapy cuts weight gain by 20% in mice
💊 Verdiva unveils once-weekly oral GLP-1 and amylin drugs
🚀 Viking begins Phase 3 trials for dual GLP-1/GIP agonist
📞 Protagonist to reveal new oral obesity drug June 30
⚖️ Novo cuts ties with Hims over Wegovy compounding
🤝 Silo & Hoth partner on GDNF-based biologic therapy
🇨🇳 China approves dual GLP-1/glucagon drug Mazdutide
🇮🇳 Biocon exits China obesity drug market
📉 Only 1 in 12 stay on GLP-1s long-term
Whether you’re a researcher, investor, or life sciences leader, this episode delivers a concise, expert-curated view of the obesity innovation landscape.
📢 Stay Ahead in Obesity Research!
✅ Like, share, and subscribe for weekly updates
#ObesityResearch #GLP1 #Fractyl #VikingTherapeutics #Verdiva #NovoNordisk #ObesityPipeline #BiotechNews #ClinicalTrials #WeightLossDrugs #LucidQuest #PharmaInnovation #MetabolicHealth #ObesityTreatment #ChinaBiotech #HealthcareConsulting